Morgan Stanley analyst Ana Escalante downgraded Icade (CDMGF) to Equal Weight from Overweight with a price target of EUR 25, down from EUR 30. The firm says disposal of the company’s healthcare business will take more time. The firm no longer assumes special dividends in the next three years for Icade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDMGF: